Bluejay Diagnostics details SYMON-II dataset for IL-6 sepsis mortality risk evaluation
BJDX•Bluejay Diagnostics released baseline data from its SYMON-II study, which is evaluating IL-6 for 28-day mortality risk in sepsis. Preliminary analysis covered 777 patients; IL-6 performance results are expected later, after ongoing sample analysis.
1. Baseline data released
The preliminary analysis covered 777 patients and found a clinically meaningful number of deaths to support a mortality-risk evaluation. Non-survivors had greater illness severity at baseline. The Symphony IL-6 test remains in development and is not cleared for commercial clinical use in the US.
